References
- Barnes RA. Early diagnosis of fungal infection in immunocompromised patients. J Antimicrob Chemother 2008;61 (Suppl 1):i3-i
- Johnson MD, Kleinberg M, Danziger L, et al. Pharmacoeconomics of antifungal pharmacotherapy – challenges and future directions. Expert Opin Pharmacother 2005;6:2617-32
- Knapp KM, Flynn PM. Newer treatments for fungal infections. J Support Oncol 2005;3:290-8
- Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006;55:809-18
- Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-96
- Martino R, Subira M, Sureda A, et al. Amphotericin B lipid complex at 3mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. J Antimicrob Chemother 1999;44:569-72
- Mehta J, Kelsey S, Chu P, et al. Amphotericin B lipid complex for the treatment of confirmed or presumed fungal infections in immunocompromised patients with haematologic malignancies. Bone Marrow Transplant 1997;20:39-43
- Barrett JP, Vardulaki KA, Conlon C, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003;25:1295-320
- Furebring M, Öberg G, Sjölin J. Side-effects of amphotericin B lipid complex (ABLC) in the Scandinavian population. Bone Marrow Transplant 2000;25:341-3
- Grasela TH, Goodwin SD, Walawander MK, et al. Prospective surveillance of intravenous amphotericin B use patterns. Pharmacotherapy 1990;10:341-8
- Goodwin SD, Cleary JD, Walawander CA, et al. Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin Infec Dis 1995;20:755-61
- Kuti J, Kotapati S, Williams P, et al. Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 2004;22:301-10
- Wingard JR, White MH, Anaissie E, et al. A randomised, double blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropaenia. Clin Infect Dis 2000;31:1155-63
- Subira M, Martino R, Gomez L, et al. Low dose amphotericin B lipid complex vs conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with haematologic malignancies – a randomised, controlled trial. Eur J Haematol 2004;72:342-7
- Pappas PG. Amphotericin B lipid complex in the treatment of invasive fungal infections: results of the Collaborative Exchange of Antifungal Research (CLEAR), an industry-supported patient registry. Clin Infect Dis 2005;40:S379-83